热门资讯> 正文
布里斯托尔加速批准伊伯多胺治疗多发性骨髓瘤
2026-08-14 05:29
- The US FDA granted accelerated approval to Bristol Myers Squibb's (BMY) Zenbexus (iberdomide), in combination with Johnson & Johnson's (JNJ) Darzalex (daratumumab), hyaluronidase-fihj and dexamethasone, as a second-line treatment for multiple myeloma.
- Approval was based on the results of the EXCALIBER-RRMM trial, which had a primary endpoint of minimal residual disease (MRD)-negative complete response at any time. Those on the iberdomide combo regimen had an MRD-negative CR rate of 41% compared to 21% in the daratumumab, hyaluronidase-fihj and dexamethasone group.
- Labeling for Zenbexus includes a boxed warning for embryo-fetal toxicity and serious venous and arterial thromboembolism. As a result, the drug is only available through a REMS program.
More on Bristol Myers Squibb
- AstraZeneca, Bristol Myers Squibb To Merge? Let's Consider The Pros And Cons
- Bristol-Myers Squibb Company (BMY) Q2 2026 Earnings Call Transcript
- Bristol-Myers Squibb Company 2026 Q2 - Results - Earnings Call Presentation
- Cytokinetics sues Bristol-Myers to avoid patent dispute
- AstraZeneca held talks with Bristol-Myers through spring, summer - FT
推荐文章
港股周报 | 恒指五连阳！周涨3.5%重返26000点；小米周内劲升13%！单季净利环比改善；医药、加密、黄金股本周齐飙升
美股前瞻 | 比特币一度突破7.8万美元！加密货币概念股盘前齐升；存储需求强劲！美光CEO称“全力生产也跟不上需求”
银色债券2026今起认购！保底息率4.25厘，每手3年累计派息至少1,275港元
华盛早报 | 贝森特两日救市！美债回购规模或超40亿美元；Anthropic冲击史上最大IPO；恒指季检结果，中际旭创、长飞光纤财报今日公布
美股前瞻 | 史诗级“轧空”来袭！比特币升破7.2万美元；业绩股齐遇冷！沃尔玛盘前大跌逾6%，阿里、网易均跌近4%
一图看懂 | AI与云业务表现强劲！阿里Q1营收2690亿元，同比增9%略超预期；阿里云外部商业化收入加速增至45%
一图看懂 | 泡泡玛特上半年营收171亿、净利50亿均大逊预期！星星人IP逆势暴涨580%；王宁称计划半年内大额回购20-50亿
Moderna暴涨177%！mRNA癌症疫苗迎来“ChatGPT时刻”？16只港美标的谁会接过下一棒？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
